Schäfer-Korting M, Korting H C, Amann F, Peuser R, Lukacs A
Pharmakologisches Institut für Naturwissenschaftler, Johann Wolfgang-Goethe Universität, Frankfurt, Germany.
Antimicrob Agents Chemother. 1991 Oct;35(10):2053-6. doi: 10.1128/AAC.35.10.2053.
The relevance of intense protein binding to the antifungal activity of azole compounds is still a matter of debate. The influence of albumin on the antimicrobial activity of ketoconazole and itraconazole, which exhibit very strong plasma protein binding (99 and 99.8%), was evaluated in vitro. Candida albicans was exposed to continuously changing azole concentrations corresponding to drug levels in serum following an oral dose of 200 mg. Total as well as free drug levels in serum were simulated. The incubation medium was free of proteins or contained 4% human serum albumin. Itraconazole levels reflecting free drug concentrations in humans did not reduce the growth rate of C. albicans, as compared with controls (difference in the log CFU per milliliter at 12 h, 0.03 +/- 0.09), whereas total drug levels were as active in the presence of 4% albumin (mean difference, -0.61) as in its absence (-0.75). The same was true for ketoconazole, except that free drug levels were also active (-1.21 versus -1.39 for total drug levels). This result was due to the higher ketoconazole levels in humans. Thus, in terms of routine susceptibility testing, in vitro total drug levels can be considered relevant.
强烈的蛋白结合与唑类化合物抗真菌活性之间的相关性仍是一个有争议的问题。对酮康唑和伊曲康唑(它们表现出非常强的血浆蛋白结合率,分别为99%和99.8%),评估了白蛋白对其抗菌活性的影响。白色念珠菌暴露于与口服200 mg剂量后血清中药物水平相对应的不断变化的唑类浓度下。模拟了血清中的总药物水平和游离药物水平。孵育培养基不含蛋白质或含有4%的人血清白蛋白。与对照相比,反映人体游离药物浓度的伊曲康唑水平并未降低白色念珠菌的生长速率(12小时时每毫升对数CFU的差异为0.03±0.09),而在存在4%白蛋白的情况下总药物水平的活性(平均差异为-0.61)与不存在时(-0.75)相同。酮康唑的情况也是如此,只是游离药物水平也具有活性(总药物水平为-1.21对-1.39)。这一结果是由于人体中酮康唑水平较高。因此,就常规药敏试验而言,体外总药物水平可被视为具有相关性。